In addition, a randomized controlled trial based in Japan found that the use of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in individuals with CKD and hyperuricemia slightly changed serum creatinine levels [8]. Here, XDH is linked to chronic kidney disease.